Patient Adherence Program
Program overview
This sponsored program aims to provide education and support to patients prescribed Reaptan® for the treatment of high blood pressure.
The program consists of a series of 9 messages delivered over 5 months, with information and topics focused on the quality use of medicines and improving medication adherence and treatment outcomes for patients.
When?
From 18 January 2024
For which patients?
Messages will be delivered to patients who are signed up to MedAdvisor and dispensed Reaptan® (perindopril/amlodipine).

© 2026 MedAdvisor International Pty Ltd